Qishen Taohong Granule as Adjuvant Therapy for Improving Cardiac Function and Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled Trial

Xing-xing LI; Yang WU; Zong-jing FAN; Jie CUI; Dong LI; Quan LIN; Rui ZHUANG; Rong-kun YAN; Qian LIN; Yan LI

doi:10.1007/s11655-021-2866-z

Your Location：

Home >

Browse articles >

Qishen Taohong Granule as Adjuvant Therapy for Improving Cardiac Function and Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled Trial

Original Article | Updated：2022-03-18

- Qishen Taohong Granule as Adjuvant Therapy for Improving Cardiac Function and Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled Trial
- Chinese Journal of Integrative Medicine Vol. 28, Issue 1, Pages: 12-19(2022)
- Affiliations：
  
  1.Department of Graduate School, Beijing University of Chinese Medicine, Beijing (100029), China
  2.Department of Cardiology,Dongfang Hospital, Beijing University of Chinese Medicine, Beijing(100078), China
  3.Department of Cardiology, Xiyuan Hospital,China Academy of Chinese Medical Sciences, Beijing (100091),China
  4.Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing (100700), China
- Author bio：
  
  Dr. LI Yan, E-mail: 15801434320@163.com
- Funds：
- DOI：10.1007/s11655-021-2866-z
  CLC：
- Published：01 January 2022，
  
  Published Online：13 August 2021，
  
  Accepted：03 December 2020
Scan for full text
Xing-xing LI, Yang WU, Zong-jing FAN, et al. Qishen Taohong Granule as Adjuvant Therapy for Improving Cardiac Function and Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled Trial. [J]. Chinese Journal of Integrative Medicine 28(1):12-19(2022)
DOI：

Xing-xing LI, Yang WU, Zong-jing FAN, et al. Qishen Taohong Granule as Adjuvant Therapy for Improving Cardiac Function and Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled Trial. [J]. Chinese Journal of Integrative Medicine 28(1):12-19(2022) DOI： 10.1007/s11655-021-2866-z.

摘要

目的:

证实芪参桃红颗粒能够改善慢性心力衰竭 (CHF) 患者的心功能和生活质量.

方法:

本研究是一项单中心、前瞻性、随机、对照临床试验. 将76例27-84岁New York Heart Association (NYHA) Ⅱ或Ⅲ级、CHF分期C期的CHF患者随机等比例分配接受芪参桃红颗粒或曲美他嗪治疗

两组患者均服用治疗CHF的西医常规药物. 研究周期为4周. 主要结局指标为心功能 (NYHA分级和左室射血分数) 、CHF患者中西医结合生存量表评估生活质量. 次要结局指标包括6分钟步行试验 (6MWT) 、中医证候积分、症状和体征积分以及N端B型利钠肽原 (NT-proBNP). 所有指标均在入组时和试验结束时测量.

结果:

4周随访时

芪参桃红颗粒组NYHA分级有效率优于曲美他嗪组 (74.29% vs. 54.29%

0.05) . 但两组治疗后左室射血分数比较

差异无统计学意义 (

0.05) . 芪参桃红颗粒组和曲美他嗪组患者中西医结合生存量表评分分别提高了 (13.82±6.04) 分和 (7.49±2.28) 分 (

0.05) . 亚组分析显示

芪参桃红颗粒组在生理功能、角色限制和活力方面评分明显优于曲美他嗪组[ (15.76±7.85) vs. (7.40±3.36)

0.05; (16.00±8.35) vs. (10.53±4.64)

0.05; (15.31±8.09) vs. (7.89±4.60)

0.05]. 与曲美他嗪组比较

芪参桃红颗粒治疗组患者在6MWT、中医证候积分、气短、乏力、气喘、水肿和NT-proBNP方面也表现出优势性. 两组治疗期间均未发生明显的不良反应或不良心血管事件.

结论:

芪参桃红颗粒联合西医常规治疗可明显改善NYHA Ⅱ或Ⅲ级、ACC/AHA CHF分期C期患者的心功能及生活质量 (临床研究注册号: ChiCTR 1900022036)

Abstract

Objective:

To confirm the improvement of cardiac function and quality of life (QoL) in patients with chronic heart failure (CHF) via Chinese medicine (CM) Qishen Taohong Granule (QTG).

Methods:

This study was a single-center

prospective

randomized

controlled clinical trial. Seventy-six patients from 27 to 84 years old diagnosed with CHF New York Heart Association (NYHA) class Ⅱ or Ⅲ in stage C were enrolled and randomly assigned at a 1:1 ratio to receive QTG or trimetazidine (TMZ)

in addition to their standard medications for the treatment of CHF. The study period was 4 weeks. The primary outcomes included cardiac function evaluated by NYHA classification and left ventricular ejection fraction (LVEF)

as well as QoL evaluated by CHF Integrated Chinese and Western Medicine Survival Scale (CHFQLS). The secondary outcomes included 6-min walking test (6MWT)

CM syndrome score

symptom and sign scores and N-terminal pro-B-type natriuretic peptide level (NT-proBNP). All indices were measured at baseline and the end of the trial.

Results:

At the 4-week follow-up period

the effective rate according to NYHA classification in the QTG group was better than that in the TMZ group (74.29% vs. 54.29%

0.05). But there was no significant difference in posttreatment level of LVEF between the two groups (

0.05). The CHFQLS scores improved by 13.82±6.04 vs. 7.49±2.28 in the QTG and TMZ groups

respectively (

0.05). Subgroup analysis of the CHFQLS results showed that physiological function

role limitation and vitality were significantly higher in the QTG group than in the TMZ group (15.76±7.85 vs. 7.40±3.36

0.05; 16.00±8.35 vs. 10.53±4.64

0.05; 15.31±8.09 vs. 7.89±4.60

0.05). Compared with TMZ group

treatment with QTG also demonstrated superior performance with respect to 6MWT

CM syndrome

shortness of breath

fatigue

gasping

general edema and NT-proBNP level. No significant adverse reactions or adverse cardiac events occurred during treatment in either group.

Conclusion:

In addition to conventional treatments

the use of QTG as an adjuvant therapy significantly improved cardiac function and QoL in patients with CHF class Ⅱ or Ⅲ in stage C. [Registration No. ChiCTR1900022036 (retrospectively registered)]

关键词

Keywords

chronic heart failureChinese medicineQishen Taohong Granulecardiac functionquality of life

references

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019;139:e56-e528.

Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J,Hernandez AF, O'Connor CM, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA 2020;324:1512-1521.

Huang Y, Kwan KKL, Leung KW, Yao P, Wang H, Dong TT,et al. Ginseng extracts modulate mitochondrial bioenergetics of live cardiomyoblasts: a functional comparison of different extraction solvents. J Ginseng Res 2019;43:517-526.

Li Y, Nong YB, Lin Q. Correlation between heart-qi deficiency syndrome of chronic heart failure and level of myocardial creatine. J Beijing Univ Tradit Chin Med (Chin)2010;33:825-828, 833.

Wu S, Chang G, Gao L, Jiang D, Wang L, Li G, et al.Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy. J Mol Med (Berl) 2018;96:791-806.

Su JZ, Li LW, Lin Q. Lin Qian's experience in treating chronic heart failure with integrated traditional Chinese and Western medicine. Chin J Basic Med Tradit Chin Med (Chin)2016;22:128-130.

Sui YB, Wang Y, Liu L, Liu F, Zhang YQ. Astragaloside Ⅳalleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway. Pharm Biol 2019;57:48-54.

Wang L, Yu J, Fordjour PA, Xing X, Gao H, Li Y, et al.Danshen Injection prevents heart failure by attenuating post-infarct remodeling. J Ethnopharmacol 2017;205:22-32.

Liu Y, Xu W, Xiong Y, Du G, Qin X. Evaluations of the effect of Huangqi against heart failure based on comprehensive echocardiography index and metabonomics. Phytomedicine 2018;50:205-212.

Wu HJ, Yuan GG, eds. Treatment of heart failure with integrated Chinese and Western medicine. Beijing:Tsinghua University Press; 2008:76-77.

Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International society for heart and lung transplantation. Circulation 2009; 119:e391-479.

Qi P, Zhang CX. The latest guideline for the diagnosis and treatment of adult heart failure in ACC/AHA2009 (1). Chin J Health Care Med (Chin) 2010;12:323-325.

Zheng XY, eds. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: China Medical Science Press; 2002:77-85.

Wan J, Lin Q, Su JZ, Tan H, Li PH. Evaluation of standard validity of quality of life scale for chronic heart failure with integrated Chinese and Western medicine. Chin J Integr Tradit West Med (Chin) 2016;36:1300-1303.

Xiang N. Clinical observation of Wenyang Yiqi Decoction in treating chronic cardiac failure with deficiency of yang qi and blood stasis [dissertation]. Wuhan: Hubei University of Chinese Medicine; 2019.

He SL, Li YJ, eds. Methodology of medical research.Beijing: People's Military Medicine Press; 2004:601.

Chinese Society of Cardiovascular Diseases, Chinese Journal of Cardiovascular Diseases Editorial Committee.Chinese heart failure diagnosis and treatment guidelines 2014. Chin J Cardio Dis (Chin) 2014;42:98-122.

Pellicori P, Khan MJI, Graham FJ, Cleland JGF. New perspectives and future directions in the treatment of heart failure. Heart Fail Rev 2020;25:147-159.

Zhao K, Tian JF, Zhao C, Yuan F, Gao ZY, Li LZ, et al.Effectiveness of integrative medicine therapy on coronary artery disease prognosis: a real-world study. Chin J Integr Med 2019;25:9-15.

Li J, Guan XK, Liu RX. Role of Chinese herbal medicines in regulation of energy metabolism in treating cardiovascular diseases. Chin J Integr Med 2019;25:307-315.

Wei Y, Wu Y, Feng K, Zhao Y, Tao R, Xu H, et al.Astragaloside Ⅳ inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway. J Ethnopharmacol 2020;249:112404.

Wang X, Guo D, Li W, Zhang Q, Jiang Y, Wang Q, et al.Danshen (Salvia miltiorrhiza) restricts MD2/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure. J Cell Mol Med 2020;24:10677-10692.

Han CK, Tien YC, Jine-Yuan Hsieh D, Ho TJ, Lai CH, Yeh YL, et al. Attenuation of the LPS-induced, ERK-mediated upregulation of fibrosis-related factors FGF-2, uPA, MMP-2,and MMP-9 by Carthamus tinctorius L in cardiomyoblasts.Environ Toxicol 2017;32:754-763.

Psotka MA, Teerlink JR. Assessing the lifetime benefit of heart failure therapies. Lancet 2020;396:75-77.

Bredy C, Ministeri M, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, et al. New York Heart Association (NYHA)classification in adults with congenital heart disease:relation to objective measures of exercise and outcome.Eur Heart J Qual Care Clin Outcomes 2018;4:51-58.

Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of dapagliflozin on symptoms,function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial.Circulation 2020;141:90-99.

Lin Q, Nong YB, Wan J, Lu JJ, Wen ZH, An C. A clinical study of scale for evaluating the quality of life in patients with chronic heart failure treated with traditional Chinese and western medicine. Chin J Integr Tradit West Med Intens Crit Care (Chin) 2008;3:131-134.

Peng P, Yuan WA, Hu YH, Tang J, Jiang J, Hu YY. Quality control about syndrome of traditional Chinese medicine in clinical research of Chinese materia medica as a new drug.Chin J Tradit Chin Med Phar (Chin) 2020;35:2722-2724.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation

Development of Improved Version of Quality of Life Assessment Instrument for Lung Cancer Patients Based on Traditional Chinese Medicine (QLASTCM-Lu)

Impact of Jumihaidokuto (Shi-Wei-Bai-Du-Tang) on Treatment of Chronic Spontaneous Urticaria: A Randomized Controlled Study

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Related Author

No data

Related Institution

Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Graduate School, Beijing University of Chinese Medicine

Department of Traditional Chinese Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

Shanghai Chest Hospital, Shanghai Jiaotong University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰